FDA Decision On Mylan Duragesic ANDA Upheld By D.C. Court

FDA did not err in barring Mylan's transdermal fentanyl patch from coming to market until after Johnson & Johnson/Alza's pediatric exclusivity for Duragesic expires Jan. 23, a D.C. federal court said